UBS AM’s Precigen PGEN Stock Holding History

UBS AM’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Sell	333,346 -21,213	-6%	-$91.7K	﹤0.01%	2076
2026 Q1	$1.37M	Buy	354,559 +120,712	+52%	+$495K	﹤0.01%	2204
2025 Q4	$977K	Buy	+233,847	New	+$905K	﹤0.01%	2145
2023 Q3	–	Sell	-107,073	Closed	-$113K	–	2663
2023 Q2	$113K	Hold	107,073	–	–	﹤0.01%	2635
2023 Q1	$113K	Sell	107,073 -25,810	-19%	-$37.2K	﹤0.01%	2635
2022 Q4	$202K	Hold	132,883	–	–	﹤0.01%	2444
2022 Q3	$282K	Sell	132,883 -38,155	-22%	-$80.5K	﹤0.01%	2512
2022 Q2	$229K	Buy	171,038 +73,188	+75%	+$109K	﹤0.01%	2551
2022 Q1	$206K	Hold	97,850	–	–	﹤0.01%	2672
2021 Q4	$363K	Hold	97,850	–	–	﹤0.01%	2641
2021 Q3	$488K	Hold	97,850	–	–	﹤0.01%	2512
2021 Q2	$638K	Buy	97,850 +8,019	+9%	+$56K	﹤0.01%	2437
2021 Q1	$619K	Buy	89,831 +13,000	+17%	+$110K	﹤0.01%	2309
2020 Q4	$784K	Sell	76,831 -11,200	-13%	-$72.6K	﹤0.01%	2102
2020 Q3	$308K	Hold	88,031	–	–	﹤0.01%	2296
2020 Q2	$439K	Sell	88,031 -7,293	-8%	-$24.8K	﹤0.01%	2171
2020 Q1	$324K	Sell	95,324 -14,838	-13%	-$64K	﹤0.01%	2131
2019 Q4	$604K	Buy	110,162 +14,516	+15%	+$81.7K	﹤0.01%	2162
2019 Q3	$547K	Buy	95,646 +15,917	+20%	+$108K	﹤0.01%	2250
2019 Q2	$611K	Sell	79,729 -5,123	-6%	-$27.6K	﹤0.01%	2117
2019 Q1	$446K	Buy	84,852 +4,000	+5%	+$27.7K	﹤0.01%	2156
2018 Q4	$529K	Buy	80,852 +48,675	+151%	+$545K	﹤0.01%	1971
2018 Q3	$554K	Hold	32,177	–	–	﹤0.01%	2046
2018 Q2	$449K	Sell	32,177 -14,662	-31%	-$248K	﹤0.01%	2141
2018 Q1	$718K	Hold	46,839	–	–	﹤0.01%	1883
2017 Q4	$540K	Buy	46,839 +11,104	+31%	+$165K	﹤0.01%	1943
2017 Q3	$679K	Sell	35,735 -9,047	-20%	-$186K	﹤0.01%	1843
2017 Q2	$1.08M	Buy	44,782 +11,449	+34%	+$251K	﹤0.01%	1623
2017 Q1	$661K	Buy	33,333 +4,516	+16%	+$101K	﹤0.01%	1777
2016 Q4	$694K	Sell	28,817 -9,485	-25%	-$264K	﹤0.01%	1710
2016 Q3	$1.06M	Buy	38,302 +7,830	+26%	+$207K	﹤0.01%	1670
2016 Q2	$743K	Buy	30,472 +949	+3%	+$26.9K	﹤0.01%	1774
2016 Q1	$992K	Sell	29,523 -8,254	-22%	-$260K	﹤0.01%	1639
2015 Q4	$1.13M	Buy	37,777 +505	+1%	+$17K	﹤0.01%	1691
2015 Q3	$1.18M	Hold	37,272	–	–	﹤0.01%	1657
2015 Q2	$1.8M	Buy	37,272 +10,800	+41%	+$455K	﹤0.01%	1452
2015 Q1	$1.15M	Buy	26,472 +1,779	+7%	+$63.9K	﹤0.01%	1578
2014 Q4	$650K	Buy	24,693 +6,068	+33%	+$133K	﹤0.01%	1800
2014 Q3	$331K	Buy	18,625 +4,604	+33%	+$94K	﹤0.01%	2093
2014 Q2	$337K	Hold	14,021	–	–	﹤0.01%	2108
2014 Q1	$352K	Buy	14,021 +942	+7%	+$26.1K	﹤0.01%	2083
2013 Q4	$298K	Sell	13,079 -36,099	-73%	-$729K	﹤0.01%	2141
2013 Q3	$1.11M	Buy	+49,178	New	+$1.13M	﹤0.01%	1462

Other funds holding PGEN

PCM

Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS AM's PGEN Position: Q2 2026 in Review

UBS AM reduced its Precigen (PGEN) stake by 6% in Q2 2026, selling an estimated $91.7K and leaving 333,346 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2076.

UBS AM first reported a position in PGEN in Q3 2013 and has held it in 43 quarters since. 211 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

UBS AM held 333,346 shares of Precigen worth $1.9M as of Q2 2026.
UBS AM sold 21,213 Precigen shares in Q2 2026, an estimated $91.7K.
Precigen made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2076 holding.
UBS AM first reported a position in Precigen in Q3 2013 and has held it in 43 quarters since.
211 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.